A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Phase 2
90
about 2.1 years
18+
13 sites in AZ, CA, FL +7
About this study
This trial is testing a treatment called PCS6422 with capecitabine (Cap) compared to standard dose of Cap alone for people with advanced or metastatic breast cancer. The goal is to see if PCS6422 + Cap is an effective and safe treatment option for those who can't have anthracycline- or taxane-containing therapies, or other available therapies like PD-1 or PARP inhibitors.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Capecitabine
- 2.Take PCS6422 and capecitabine
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
capecitabine
oral (Oral Tablet)
Primary: Evaluation of Objective Response Rate (ORR), Number of patients with adverse events (AEs)
Secondary: Evaluation of Disease Control Rate (DCR), Evaluation of Duration of Response (DOR), Evaluation of Progression Free Survival (PFS)
Oncology